Navigation Links
Geisinger study: Inflammatory disease causes blindness
Date:6/16/2008

DANVILLE, PA. People suffering from a type of connective tissue disease characterized by inflammation of arteries in the head are three times more likely to experience blindness, new Geisinger research shows.

In a study published in a recent edition of the Journal of Clinical Pathology, Geisinger researchers examined a disorder known as temporal arteritis. In this disease, arteries swell and restrict blood flow to the brain.

Temporal arteritis can cause headaches, jaw soreness and flu-like symptoms. Untreated, the disease can lead to blindness or stroke. The average age for disease onset is 70.

Giant cells, which are white blood cells that destroy bacteria, are often found in patients with the disease. The Geisinger study found that patients with giant cells are far more prone to blindness compared to patients without these cells.

The study also found that patients with giant cells are three times more likely to experience Polymyalgia rheumatica, an inflammatory disorder that causes muscle aches and stiffness primarily in the arms, thighs and neck.

"We need to learn more about how these giant cells work so we can limit the effects of this disease, which can cause significant problems if ignored," said Geisinger rheumatologist and lead study author Thomas Harrington, MD.


'/>"/>

Contact: Justin Walden
jawalden@Geisinger.edu
570-271-8083
Geisinger Health System
Source:Eurekalert

Page: 1

Related biology news :

1. Study: diabetic neuropathy costs billions per year in lost work time
2. Study: Fountain of youth for your heart?
3. First-ever study: lack of critical lubricant causes wear in joints
4. Mayo Clinic study: Ossurs collars superior in immobilization and reduction of pressure
5. Study: weight-loss tips differ in African-American, mainstream magazines
6. Smithsonian study: Sediment prediction tools off the mark
7. Mouse study: When it comes to living longer, its better to go hungry than go running
8. Scientists successfully treat new mouse model of inflammatory bowel disease
9. Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment
10. Antioxidant overload may underlie a heritable human disease
11. Gender, coupled with diabetes, affects vascular disease development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   ... data sensor technology, and STMicroelectronics (NYSE: ... spectrum of electronics applications, announced today the launch ... kit for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, ...
(Date:12/16/2016)... global wearable medical device market, in terms of value, is projected ... in 2016, at a CAGR of 18.0% during the forecast period. ... Growth in ... launch of a growing number of smartphone-based healthcare apps compatible with ... increasing focus on physical fitness. Furthermore, growing trend ...
(Date:12/15/2016)... 2016 Advancements in biometrics will ... and wellbeing (HWW), and security of vehicles ... passenger vehicles begin to feature fingerprint recognition, ... beat monitoring, brain wave monitoring, stress detection, ... pulse detection. These will be driven by ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... ... January 20, 2017 , ... G&L Scientific Inc, a leading ... http://www.gandlscientific.com ), has announced the opening of new offices in Cambridge, Massachusetts, strengthening ... contractors. This is the latest step in G&L’s expansion of its global clinical ...
(Date:1/21/2017)... Jan. 20, 2017 Interpace Diagnostics Group, ... that provides clinically useful molecular diagnostic tests and ... into a securities purchase agreement with three  institutional ... of common stock in a registered direct offering.  ... agreed to sell to the same investors warrants ...
(Date:1/21/2017)... --  Boston Biomedical , an industry leader in the ... pathways, today presented data from two clinical studies for ... Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in ... In a Phase Ib/II study of napabucasin – an ... pathways by targeting STAT3 – colorectal cancer (CRC) patients ...
(Date:1/20/2017)... BOSTON , Jan. 20, 2017 ... acquisition of Gen9, a pioneer in the synthesis ... Gen9,s unique expertise in assembling pathway-length synthetic DNA ... speed and capacity in the construction of new ... of industries. "Gen9 was founded to ...
Breaking Biology Technology: